MEDIFAST INC
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
MED$13.03-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating Activities | |||
| Net income (loss) | $(18,672) | $2,091 | $99,415 |
| Adjustments to reconcile net income to cash provided by operating activities | |||
| Depreciation and amortization | 14,242 | 12,707 | 13,107 |
| Non-cash lease expense | 4,624 | 4,490 | 4,607 |
| Share-based compensation | 7,639 | 7,363 | 8,188 |
| Loss on sale of disposal of property, plant and equipment | 1,373 | 89 | 1,172 |
| Realized gain on sale of investment securities | (3,310) | (95) | — |
| Amortization of discount on investment securities | (671) | (799) | (169) |
| Deferred income taxes | 11,460 | (7,403) | 1,211 |
| Unrealized (gain) loss on equity investment securities | (17) | 4,089 | (150) |
| Non-cash charges for supply chain optimization | — | 11,689 | — |
| Change in operating assets and liabilities: | |||
| Inventories | 22,193 | 12,170 | 64,265 |
| Income taxes | (6,601) | 10,212 | (9,155) |
| Prepaid expenses and other current assets | 573 | 2,471 | 5,567 |
| Other assets | (2,057) | 396 | (4,694) |
| Accounts payable and accrued expenses | (23,913) | (34,994) | (35,707) |
| Net cash flow provided by operating activities | 6,863 | 24,476 | 147,657 |
| Investing Activities | |||
| Purchase of investment securities | (84,407) | (46,595) | (59,756) |
| Proceeds from sale and maturities of investment securities | 82,093 | 27,529 | 5,192 |
| Purchase of property and equipment | (5,614) | (7,454) | (6,483) |
| Net cash flow used in investing activities | (7,928) | (26,520) | (61,047) |
| Financing Activities | |||
| Options exercised by executives and directors | — | 36 | 188 |
| Net shares repurchased for employee taxes | (369) | (836) | (3,358) |
| Cash dividends paid to stockholders | (195) | (715) | (73,017) |
| Stock repurchases | — | — | (3,602) |
| Net cash flow used in financing activities | (564) | (1,515) | (79,789) |
| Foreign currency impact | 4 | 47 | (72) |
| Increase (Decrease) in cash and cash equivalents | (1,625) | (3,512) | 6,749 |
| Cash and cash equivalents - beginning of the period | 90,928 | 94,440 | 87,691 |
| Cash and cash equivalents - end of period | $89,303 | $90,928 | $94,440 |
| Supplemental disclosure of cash flow information | |||
| Income taxes (refunded) paid | $10,465 | $(1,617) | $34,255 |
| Dividends included in accounts payable and accrued expenses | $295 | $648 | $1,407 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.